Flare-ups: New Insights into the Burden of Pain in Hidradenitis Suppurativa

Zouboulis CC, Bechara FG, Fritz K, Goebeler M, Hetzer FH, Just E, et al. S2k guideline for the treatment of hidradenitis suppurativa/acne inversa – Short version. J Dtsch Dermatol Ges 2024; 22: 868–889.

https://doi.org/10.1111/ddg.15412 DOI: https://doi.org/10.1111/ddg.15412

Surapaneni V, Milosavljevic MV, Orenstein LAV. Pain management in hidradenitis suppurativa. J Am Acad Dermatol 2024; 91: S52–S63.

https://doi.org/10.1016/j.jaad.2024.09.006 DOI: https://doi.org/10.1016/j.jaad.2024.09.006

Krajewski PK, Matusiak L, von Stebut E, Schultheis M, Kirschner U, Nikolakis G, et al. Pain in hidradenitis suppurativa: a cross-sectional study of 1,795 patients. Acta Derm Venereol 2021; 101: adv00364.

https://doi.org/10.2340/00015555-3724 DOI: https://doi.org/10.2340/00015555-3724

Sarfo A, Butt M, Kirby JS. Periodic worsening, or flare, in hidradenitis suppurativa: the perspective of people with hidradenitis. Br J Dermatol 2020; 182: 218–219.

https://doi.org/10.1111/bjd.18210 DOI: https://doi.org/10.1111/bjd.18210

Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol 2020; 82: 366–376.

https://doi.org/10.1016/j.jaad.2019.06.1301 DOI: https://doi.org/10.1016/j.jaad.2019.06.1301

Orenstein LAV, Salame N, Siira MR, Urbanski M, Flowers NI, Echuri H, et al. Pain experiences among those living with hidradenitis suppurativa: a qualitative study. Br J Dermatol 2023; 188: 41–51.

https://doi.org/10.1093/bjd/ljac018 DOI: https://doi.org/10.1093/bjd/ljac018

LeWitt TM, Mammis-Gierbolini A, Parnell M, Sarfo A, Paek SY, Benhadou F, et al. International consensus definition of disease flare in hidradenitis suppurativa. Br J Dermatol 2022; 187: 785–787.

https://doi.org/10.1111/bjd.21647 DOI: https://doi.org/10.1111/bjd.21647

van der Zee HH, Longcore M, Geng Z, Garg A. Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. J Eur Acad Dermatol Venereol 2020; 34: 1050–1056.

https://doi.org/10.1111/jdv.16023 DOI: https://doi.org/10.1111/jdv.16023